Having joined Osborne Clarke in 2007, there’s little doubt about Silvia’s specialism – she has devoted her entire career to life sciences and healthcare.
Today, Silvia applies that wealth of knowledge to her role. In doing so, she has worked with a wealth of high-profile clients, both nationally and internationally, including a long-term relationship with one of the world leaders in plasma-based products.
An expert in commercial law, Silvia is often called on for her advisory skills in commercial transactions, as well as regulatory issues around clinical trials, R&D activities and market access. In each instance, her approach is collaborative – in a sector which is evolving rapidly, Silvia works in close co-ordination with every client, keeping pace with change as it happens.
During her career Silvia has also gained considerable experience and skill in Corporate Compliance, with a particular focus in anticorruption related matters.
Insights
Impact of the Ukraine war on contract performance: force majeure?
Compassionate Use in Europe
Patient support programs: comments on Royal Decree 957/2020
Are European advertising laws ready for patient support programmes?
How to minimize corruption and bribery risks when hiring a third party
There are different laws (FCPA, UK Bribery Act, the Spanish Criminal Code, to mention some) that set out the possibility...
Amendments to the Spanish Consumer Law
On 1 January 2022 the amendments to the Spanish Consumer Law will enter into force. Such amendments are introduced by...
Support programmes offer global healthcare ways to meet patients' needs
With technological advances increasing access to patient support programmes, what legal and regulatory issues do pharmaceutical companies need to take...
Transposition of the Whistleblower Directive in Spain
The transposition period of the Directive (EU) 2019/1937 of 23 October 2019 on the protection of persons who report breaches...
Covid-19: Mitigating the increased risks of corruption in the Life Sciences and Healthcare sector
The pandemic, coupled with the significant economic downturn, continues to produce pressures on businesses that could prove to be fertile...